


BIOGEN



PHARMACHEM INDUSTRIES LIMITED

CIN NO: L51100GJ1995PLC026702

(Formerly Known as SUN TECHNO OVERSEAS LIMITED)

To,
Listing Department,
BSE Limited,
P J Tower, Dalal Street,
Mumbai-400001

Date: 19.09.2024

Ref: Scrip Code: 531752 Scrip ID: BIOGEN

Dear Sir/Madam,

Sub: Corrigendum to the Notice dated 13th August 2024 convening 29th Annual General Meeting of Biogen Pharmachem Industries Limited ("Company,") scheduled to be held on Saturday, 28th September, 2024 at 11:30 A.M. through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM")

In due compliance with the provisions of the Companies Act, 2013 read with Rules made there under Biogen Pharmachem Industries Limited ("the Company") circulated a Notice dated 13th August 2024 ("AGM Notice") to all its shareholders for convening the AGM as mentioned above.

Certain changes have been made in Item No 4 of Notice of Annual General Meeting and also in the Explanatory Statement annexed with the AGM Notice in respect of the special resolution (Item. No 4 the AGM Notice). Accordingly, vide this Corrigendum, we wish to inform our shareholders the explanatory statement part of the AGM Notice shall be read as under. Other contents of the AGM Notice remain unchanged.

This Corrigendum shall form an integral part of AGM Notice and shall also be available at Corporate Announcement Section of the Company's website www.biogenpharma.life on the website of and on the website of the Stock Exchanges i.e. BSE Limited at www.bseindia.com.

This is for your information and records.

Thanking you,

Yours faithfully,
For Biogen Pharmachem Industries Limited


Viraj Vaghela
Director
DIN- 04086976



BIOGEN PHARMACHEM INDUSTRIES LIMITED

CIN: L51100GJ1995PLC026702

Registered office: 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001

E-mail: suntechnooverseas@gmail.com; **Website:** www.biogenpharma.life

CORRIGENDUM TO THE NOTICE OF 29TH ANNUAL GENERAL MEETING

Dear Members,

This is in reference to the Notice of 29th Annual General Meeting dated August 13, 2024 ("AGM Notice") of Biogen Pharmachem Industries Limited ("the Company") to be held on Saturday, September 28, 2024 at 11:30 A.M. (IST) through Video Conference (VC)/ Other Audio-Visual Means (OAVM) facility, for seeking approval for matters contained in the said notice. The said notice has been duly dispatched to the shareholders of the Company as per the applicable laws. The Company through this corrigendum wishes to bring to the notice of the Shareholders of the Company the changes in the business number 4 for Approval for Issuance of 25,00,00,000 Fully Convertible Warrants into Equity Shares on Preferential Basis to and entities belonging to the Non-Promoter Category and also in the explanatory statement as set out for the Item No. 4, contained in the AGM Notice.

The Company through this communication wishes to bring to the notice of the Shareholders, following changes in the said AGM Notice:

Changes in Special Business No. 4:

1. Issue price of the Convertible Preferential Warrants per share Will be read as **Rs. 1.68422** at all the places where issue price is mentioned.
2. The Relevant Date, as per the provisions of Chapter V of the SEBI (ICDR) Regulations, 2018 for the determination of issue price of Warrants is will be read as **29th August 2024.**

Changes to the Explanatory Statement to Item No. 4:

1. Under the point no. 2 will read be as following,

The Board of Directors at its meeting held on 13th August 2024 had, subject to the approval of the Members and such other approvals as may be required, approved to issue and allot upto 25,00,00,000 (Twenty Five Crores) Fully convertible Warrants into Equity Shares of 25,00,00,000 (Twenty Five Crores) at price of Rs. 1.68422/- each aggregating to Rs 42,10,55,000/- (Rupees Forty Two Crores Ten Lakh Fifty Five Thousand Only)

2. Under the point no. 6 Identity of the natural persons who are the ultimate beneficial owners of the shares proposed to be allotted and / or who ultimately control the Proposed Allottees will read be as following,

Name of The Proposed Allottee	Category	Present Pre-Issue Shareholding		Proposed No. of Warrants to be Allotted	Post Issue Shareholding (Presuming Full conversion of Warrants)		Name of beneficial owners of proposed allottee
		Pre-Issue Holding	% Total Equity Capital		Post-Issue Holding	% Total Equity Capital	
M/s. PARICHAY INFRASTRUCTURE LIMITED	Non-Promoter	Nil	Nil	8,20,00,000	8,20,00,000	9.08 %	1. Albert Hines
M/s. RAMA SHIVA LEASE FINANCE PRIVATE LIMITED	Non-Promoter	Nil	Nil	8,40,00,000	8,40,00,000	9.31 %	1.Pankajkumar Ambalal Rathod
M/s. INTERFACE FINANCIAL SERVICES LIMITED	Non-Promoter	Nil	Nil	8,40,00,000	8,40,00,000	9.31 %	1.Prakashbhai Pravinbhai Dataniya

All other particulars and details remain unchanged. The corrigendum shall be read in conjunction with the Notice dated August 13, 2024 together with explanatory statement. This corrigendum is also available on the company's website (www.biogenpharma.life), and on the website of BSE Limited (www.bseindia.com).

By Order of the Board
For, BIOGEN PHARMACHEM INDUSTRIES LIMITED

Place: Rajkot
Date: 19.09.2024

NIRAJ VAGHELA
Chairman
DIN: 09096576